NEW YORK — Stryker Corporation (NYSE: SYK) underperformed in the third quarter as near-term operational challenges overshadowed the durability of its core business, according to Mar Vista Investment Partners' Q3 2026 investor letter.
The medical-device maker closed Oct. 8 at $276.97, down approximately 21 percent year-to-date, trading in a 52-week range of $267 to $392.55. The company carries a market capitalization of $106.24 billion on trailing twelve-month revenue of $25.84 billion.
Mar Vista's U.S. Quality Strategy returned 1.45 percent in Q3, trailing the Russell 1000's 1.79 percent gain and the S&P 500's 2.30 percent advance. Stryker's weakness in medical devices, combined with headwinds in materials and healthcare holdings, offset strength in information technology, consumer discretionary, and financials.
Stryker's Q3 deterioration was not a franchise breakdown. Management had expected U.S. orthopedic procedure volumes to accelerate after a robust June, but July and August produced only normal seasonality and weaker-than-expected hip and knee implant demand. Longer procedure lead times and patient deferrals tied to inflation and rising out-of-pocket costs depressed volumes.
Company-specific problems compounded the macro headwind. European hip sales remained weak during a competitive gap from the company's missing hip impactor product. A manufacturing and supply disruption in Peripheral Vascular, initially expected to resolve in Q3, extended into Q4. A March cyberattack that disrupted order processing, manufacturing, and shipping forced procedure rescheduling and operational delays earlier in the year.
Mar Vista increased its Nvidia holdings during the quarter while reducing Apple exposure. The firm expressed caution entering Q4, citing elevated interest rates, energy costs, and stretched valuations, though it acknowledged artificial intelligence's real long-term potential.
